Radioligand therapy — a new, innovative radiation treatment — is now offered at MultiCare Cancer Institute for individuals with advanced prostate cancer. Unlike conventional radiation treatments, radioligand therapy uses specialized molecules called radioligands that deliver radiation directly to prostate cancer cells, reducing exposure to surrounding healthy tissues.
How it works
Radioligand treatment combines a cancer-targeting compound with a radioactive isotope. The compound locates prostate cancer cells by detecting prostate-specific membrane antigen (PSMA), a protein that is found on most prostate cancer cells. When the compound binds to these cells, it delivers targeted radiation to destroy them.
Who it’s for
This targeted therapy is an option for those with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC) that is no longer responding to hormone therapy.
Benefits of radioligand treatment
- Precision targeting of cancer cells
- Fewer side effects compared to traditional treatments
- Improved quality of life
- Delayed cancer progression
Is radioligand treatment right for you?
MultiCare Cancer Institute’s extensive team of cancer specialists deliver the care you need and the support you deserve. Talk to your care team about radioligand therapy and if it may be right for you.
Why choose MultiCare Cancer Institute
- Access to cutting-edge treatments and clinical trials close to home
- Collaborative care team and support services
- Personalized care at every step of your cancer journey
- Our commitment to cancer care research and innovation
Provider perspectives
“Getting a new opportunity that gives our patients options, other than chemo, and a break from those side effects is a wonderful thing.”
— Jennifer Slim, DO, MultiCare Cancer Institute medical oncologist
“With the new FDA indication that a patient isn’t required to have gone through chemo, we’re able to expand the number of patients we can give this treatment to.”
— Susan Guo, MD, MultiCare Cancer Institute radiation oncologist
Managing metastatic prostate cancer with innovative care
A cutting-edge radioligand therapy is changing prostate cancer care by precisely targeting cancer cells while minimizing damage to healthy tissue. Patients like Timothy Taylor are seeing remarkable results, including drops in PSA levels and improved outcomes.
Find care
Talk to your cancer care team about a referral for Radioligand Therapy.